RMD
ResMed Inc. Healthcare - Medical Instruments & Supplies Investor Relations →
ResMed Inc. (RMD) closed at $224.99 as of 2026-09-18, trading 4.2% above its 200-week moving average of $215.93. The stock moved further from the line this week, up from 1.1% last week. The 14-week RSI sits at 63, indicating neutral momentum.
Trading volume is running at 1.7x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.13 ratio) is neutral — neither side is clearly dominating.
Over the past 1585 weeks of data, RMD has crossed below its 200-week moving average 13 times. On average, these episodes lasted 13 weeks. Historically, investors who bought RMD at the start of these episodes saw an average one-year return of +30.4%.
With a market cap of $32.5 billion, RMD is a large-cap stock. The company generates a free cash flow yield of 2.9%. Return on equity stands at 24.3%, indicating strong profitability. The stock trades at 4.9x book value.
RMD passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow.
Over the past 30.4 years, a hypothetical investment of $100 in RMD would have grown to $25318, compared to $1924 for the S&P 500. That represents an annualized return of 20.0% vs 10.2% for the index — confirming RMD as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been growing at a 42.8% compound annual rate, with 4 consecutive years of positive cash generation.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: RMD vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After RMD Crosses Below the Line?
Across 13 historical episodes, buying RMD when it crossed below its 200-week moving average produced an average return of +31.6% after 12 months (median +35.0%), compared to +14.2% for the S&P 500 over the same periods. 100% of those episodes were profitable after one year. After 24 months, the average return was +61.5% vs +37.5% for the index.
Each line shows $100 invested at the moment RMD crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices RMD would reach each dislocation threshold.
Dislocation Price Levels
Prices where RMD's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-10-29.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $173.00 | Unusually cheap — analysis point |
| Value | +1σ | $186.47 | Cheap vs. own history |
| Fair Value | +0σ | $202.22 | Historical mean behavior |
| Expensive | -1σ | $220.87 | Expensive vs. own history |
| Deep Expensive | -2σ | $243.31 | Unusually expensive — analysis point |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $2.89 | $2.95 | +2.0% |
| 2026-04-30 | $2.80 | $2.86 | +2.1% |
| 2026-01-29 | $2.72 | $2.81 | +3.1% |
| 2025-10-30 | $2.50 | $2.55 | +2.0% |
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
the write-ups I read Simply Wall St · Visual company reports and write-ups. Free tier covers five reports a month. referral
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are analysis points: prices at which the yield deviation becomes unusual enough to justify the work. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from RMD's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. Each one is an analysis point, a reason to open the filings. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
RMD has crossed below its 200-week MA 13 times with an average 1-year return of +30.4% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| May 1996 | May 1996 | 1 | 0.9% | +55.6% | +32250.3% |
| May 2002 | Aug 2002 | 14 | 21.4% | +25.3% | +3628.9% |
| Aug 2002 | Oct 2002 | 9 | 15.5% | +39.2% | +3409.6% |
| Nov 2002 | Apr 2003 | 21 | 13.5% | +20.3% | +3268.8% |
| Jun 2008 | Aug 2008 | 8 | 11.4% | +4.8% | +1326.1% |
| Oct 2008 | Feb 2009 | 17 | 23.1% | +34.9% | +1510.4% |
| Feb 2009 | Aug 2009 | 24 | 22.7% | +40.7% | +1236.4% |
| Nov 2011 | Jan 2012 | 8 | 4.3% | +63.5% | +992.3% |
| Jul 2023 | Apr 2024 | 38 | 34.9% | +26.1% | +29.6% |
| May 2024 | Jun 2024 | 1 | 1.0% | +19.7% | +11.4% |
| Jun 2024 | Jul 2024 | 6 | 8.4% | +24.4% | +11.7% |
| Mar 2025 | Apr 2025 | 3 | 5.0% | +10.2% | +11.3% |
| Apr 2026 | Aug 2026 | 15 | 12.8% | N/A | +10.4% |
| Average | 13 | — | +30.4% | — |
Frequently Asked Questions
Is RMD below its 200-week moving average?
No. ResMed Inc. (RMD) is currently 4.2% above its 200-week moving average of $215.93. It would need to fall to $215.93 to cross below the line.
What is RMD's 200-week moving average price?
ResMed Inc.'s 200-week moving average is $215.93 as of 2026-09-18. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when RMD drops below its 200-week moving average?
RMD has crossed below its 200-week moving average 13 times in our data. On average, buying at that moment produced a one-year return of +30.4%. These dips have historically been decent entry points. These episodes lasted 13 weeks on average.
Is RMD a good value right now?
Here's what our data says about RMD as of 2026-09-18: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 63. Free cash flow yield is 2.9%. Return on equity is 24.3%. Price-to-book is 4.9x. This is not a buy or sell recommendation — always do your own research.
How does RMD compare to the S&P 500?
Over the past 30.4 years, $100 invested in RMD would have grown to $25318, compared to $1924 for the S&P 500. That's 20.0% annualized vs 10.2% for the index. RMD has outperformed the broader market over this period.
Does RMD pay a dividend?
Yes. ResMed Inc. currently pays a dividend yield of 117.00%.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-09-18